Payment overview · 2025
General Payments
29 reported records · 10 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|Radiology|Vascular & Interventional Radiology · OCEANSIDE, CA · NPI 1245337302
Verified facts
CMS Open Payments records show Justin Mathias Gooding, M.D. received $2,403.57 in general payments during 2025 across 29 reported records.
Penumbra, Inc. accounted for 65.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
29 reported records · 10 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,573.68 | 65.5% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $198.59 | 8.3% | 5 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$159.83 | 6.7% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $150.44 | 6.3% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $80.14 | 3.3% | 4 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $76.34 | 3.2% | 3 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $57.15 | 2.4% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $45.57 | 1.9% | 1 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $35.54 | 1.5% | 1 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $26.29 | 1.1% | 2 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,432.45 | 28 |
| Travel and Lodging | $971.12 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,396.98 | 3 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $176.70 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $150.44 | 1 | 2025 |
Source payment records
|
|||||
| SOLITAIRE X Normalized: solitaire x |
Device | Medtronic, Inc. | $125.24 | 3 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $89.68 | 2 | 2025 |
Source payment records
|
|||||
| EMBOLD Fibered Normalized: embold fibered |
Device | Boston Scientific Corporation | $67.34 | 2 | 2025 |
Source payment records
|
|||||
| Passeo-18 Normalized: passeo 18 |
Device | BIOTRONIK INC. | $45.57 | 1 | 2025 |
Source payment records
|
|||||
| Rubicon 18 Normalized: rubicon 18 |
Device | Boston Scientific Corporation | $41.57 | 1 | 2025 |
Source payment records
|
|||||
| COOLIEF COOLED RADIOFREQUENCY Normalized: coolief cooled radiofrequency |
Device | Avanos Medical | $35.54 | 1 | 2025 |
Source payment records
|
|||||
| AXIUM PRIMETM Normalized: axium primetm |
Device | Medtronic, Inc. | $34.59 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $34.48 | 1 | 2025 |
Source payment records
|
|||||
| COVERA Normalized: covera |
Device | Bard Peripheral Vascular, Inc. | $24.91 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| GORE DRYSEAL FLEX Introducer Sheath Normalized: gore dryseal flex introducer sheath |
Device | W. L. Gore & Associates, Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| ZOOM 88 LARGE DISTAL PLATFORM SUPPORT Normalized: zoom 88 large distal platform support |
Device | Imperative Care, Inc | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| GORE VIATORR TIPS Endoprosthesis with Controlled Expansion Normalized: gore viatorr tips endoprosthesis with controlled expansion |
Device | W. L. Gore & Associates, Inc. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Crosser IQ Normalized: crosser iq |
Device | Bard Peripheral Vascular, Inc. | $18.39 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| ZOOM 88-T LARGE DISTAL PLATFORM Normalized: zoom 88 t large distal platform |
Device | Imperative Care, Inc | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,403.57 · 29 records | Penumbra, Inc. | AXIUM PRIMETM, COOLIEF COOLED RADIOFREQUENCY, COVERA, Crosser IQ, EMBOLD Fibered, GORE DRYSEAL FLEX Introducer Sheath, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE VIATORR TIPS Endoprosthesis with Controlled Expansion, General - Vascular Intervention, Indigo System, LUTONIX Drug Coated Balloon, Passeo-18, RUBY Coil, Rubicon 18, SOLITAIRE X, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Venovo, ZOOM 88 LARGE DISTAL PLATFORM SUPPORT, ZOOM 88-T LARGE DISTAL PLATFORM | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error